
MPLT Stock Forecast & Price Target
MPLT Analyst Ratings
Bulls say
MapLight Therapeutics is a promising clinical-stage biopharmaceutical company that has shown potential in developing circuit-specific pharmacotherapies for central nervous system disorders through its discovery platform. The company has a strong cash position and upcoming partnerships with the FDA, indicating a clear path forward for its product candidate, ML-007C-MA, in both schizophrenia and Alzheimer's disease psychosis. With potential differentiations in dosing convenience and timepoints for measuring primary endpoints, and a favorable safety profile compared to competitors, MapLight Therapeutics has solid prospects for success in the market.
Bears say
MapLight Therapeutics is facing challenges with their ML-007C-MA product candidate, as the once-daily dosing regimen has shown only mild improvement over placebo on the primary endpoint and may not be as potent as originally expected. Additionally, the company has faced failures in Phase 2 trials and will need to test higher doses in Phase 3. Recent collaborations and financial metrics have also been negative, contributing to a negative outlook for the company.
This aggregate rating is based on analysts' research of MapLight Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
MPLT Analyst Forecast & Price Prediction
Start investing in MPLT
Order type
Buy in
Order amount
Est. shares
0 shares